Top

General Thoracic and Cardiovascular Surgery

Published in:

11-05-2022 | NSCLC | Original Article

Lobe-specific nodal dissection with intraoperative frozen section analysis for clinical stage-I non-small cell lung cancer: a validation study by propensity score matching

Authors: Mitsuhiro Isaka, Hideaki Kojima, Toru Imai, Hayato Konno, Tetsuya Mizuno, Toshiyuki Nagata, Shinya Katsumata, Takuya Kawata, Takashi Nakajima, Yasuhisa Ohde

Published in: General Thoracic and Cardiovascular Surgery | Issue 11/2022

Abstract

Objective

Lobe-specific nodal dissection (LND) is increasingly used for non-small cell lung cancer (NSCLC) in Japan; however, its treatment validity remains unclarified. Since 2013, LND has been used as a standard procedure for clinical stage-I (c-stage-I) NSCLC at our institution. We aimed to evaluate its validity using intraoperative frozen section analysis (FSA) for c-stage-I NSCLC.

Methods

The participants comprised patients with NSCLC who underwent LND between 2013 and 2016 (n = 307) or systematic nodal dissection (SND) between 2002 and 2013 (n = 367) for c-stage-I disease. FSA was routinely performed in LND to examine at least three stations. Outcomes were compared between the LND and SND groups. Patients in whom LND was converted to SND due to metastasis on FSA of the sampled lymph node were still categorized into the LND group, i.e., intention-to-treat analysis. The prognostic impact was compared using propensity score matching.

Results

The rate of conversion from LND to SND was 10.4%. Of the patients converted to SND, 12.5% had metastases outside the LND area. False-negative N2 results were detected in only 0.7% of the LND group patients after FSA. After matching, each group had 220 patients. There were no significant between-group differences in the lymph-node recurrence rate (7% vs. 6%), 5-year recurrence-free survival (80.1% vs. 79.0%), and overall survival (90.4% vs. 90.3%).

Conclusions

LND with intraoperative FSA is a valid modality that could serve as a standard surgical procedure for c-stage-I NSCLC. Intraoperative FSA may lower the residual lymph-node metastasis risk in LND.

Available only for authorised users

Okada M, Tsubota N, Yoshimura M, Miyamoto Y. Proposal for reasonable mediastinal lymphadenectomy in bronchogenic carcinomas: role of subcarinal nodes in selective dissection. J Thorac Cardiovasc Surg. 1998;116:949–53. https://doi.org/10.1016/S0022-5223(98)70045-5.CrossRefPubMed

Asamura H, Nakayama H, Kondo H, Tsuchiya R, Naruke T. Lobe-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis. J Thorac Cardiovasc Surg. 1999;117:1102–11. https://doi.org/10.1016/s0022-5223(99)70246-1.CrossRefPubMed

Watanabe S, Asamura H, Suzuki K, Tsuchiya R. The new strategy of selective nodal dissection for lung cancer based on segment-specific patterns of nodal spread. Interact Cardiovasc Thorac Surg. 2005;4:106–9. https://doi.org/10.1510/icvts.2004.098814.CrossRefPubMed

Okada M, Sakamoto T, Yuki T, Mimura T, Miyoshi K, Tsubota N. Selective mediastinal lymphadenectomy for clinico-surgical stage I non-small cell lung cancer. Ann Thorac Surg. 2006;81:1028–32. https://doi.org/10.1016/j.athoracsur.2005.09.078.CrossRefPubMed

Ishiguro F, Matsuo K, Fukui T, Mori S, Hatooka S, Mitsudomi T. Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: a large-scale retrospective cohort study applying a propensity score. J Thorac Cardiovasc Surg. 2010;139:1001–6. https://doi.org/10.1016/j.jtcvs.2009.07.024.CrossRefPubMed

Maniwa T, Okumura T, Isaka M, Nakagawa K, Ohde Y, Kondo H. Recurrence of mediastinal node cancer after lobe-specific systematic nodal dissection for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2013;44:e59-64. https://doi.org/10.1093/ejcts/ezt195.CrossRefPubMed

Adachi H, Sakamaki K, Nishii T, Yamamoto T, Nagashima T, Ishikawa Y, et al. Lobe-specific lymph node dissection as a standard procedure in surgery for non-small cell lung cancer: a propensity score matching study. J Thorac Oncol. 2017;12:85–93. https://doi.org/10.1016/j.jtho.2016.08.127.CrossRefPubMed

Zhao Y, Mao Y, He J, Gao S, Zhang Z, Ding N, et al. Lobe-specific lymph node dissection in clinical stage IA solid-dominant non-small-cell lung cancer: a propensity score matching study. Clin Lung Cancer. 2021;22:e201–10. https://doi.org/10.1016/j.cllc.2020.09.012.CrossRefPubMed

Hishida T, Miyaoka E, Yokoi K, Tsuboi M, Asamura H, Kiura K, et al. Lobe-specific nodal dissection for clinical stage I and II NSCLC: Japanese multi-institutional retrospective study using a propensity score analysis. J Thorac Oncol. 2016;11:1529–37. https://doi.org/10.1016/j.jtho.2016.05.014.CrossRefPubMed

10.

Endo S, Ikeda N, Kondo T, Nakajima J, Kondo H, Yokoi K, et al. Model of lung cancer surgery risk derived from a Japanese nationwide web-based database of 78 594 patients during 2014–2015. Eur J Cardiothorac Surg. 2017;52:1182–9. https://doi.org/10.1093/ejcts/ezx190.CrossRefPubMedPubMedCentral

11.

Watanabe S, Suzuki K, Asamura H. Superior and basal segment lung cancers in the lower lobe have different lymph node metastatic pathways and prognosis. Ann Thorac Surg. 2008;85:1026–31. https://doi.org/10.1016/j.athoracsur.2007.10.076.CrossRefPubMed

12.

Aokage K, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Subcarinal lymph node in upper lobe non-small cell lung cancer patients: is selective lymph node dissection valid? Lung Cancer. 2010;70:163–7. https://doi.org/10.1016/j.lungcan.2010.02.009.CrossRefPubMed

13.

Sakao Y, Okumura S, Mingyon M, Uehara H, Ishikawa Y, Nakagawa K. The impact of superior mediastinal lymph node metastases on prognosis in non-small cell lung cancer located in the right middle lobe. J Thorac Oncol. 2011;6:494–9. https://doi.org/10.1097/JTO.0b013e31820b8891.CrossRefPubMed

14.

Hattori A, Matsunaga T, Takamochi K, Oh S, Suzuki K. Neither maximum tumor size nor solid component size is prognostic in part-solid lung cancer: impact of tumor size should be applied exclusively to solid lung cancer. Ann Thorac Surg. 2016;102:407–15. https://doi.org/10.1016/j.athoracsur.2016.02.074.CrossRefPubMed

15.

Isaka M, Kojima H, Takahashi S, Omae K, Ohde Y. Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: implications for adjuvant therapy. Lung Cancer. 2018;115:28–33. https://doi.org/10.1016/j.lungcan.2017.11.014.CrossRefPubMed

16.

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.CrossRefPubMedPubMedCentral

17.

Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568–77. https://doi.org/10.1097/JTO.0b013e3181a0d82e.CrossRefPubMed

18.

Kim HR, Kim DJ, Lee WW, Jheon S, Sung SW. The significance of maximum standardized uptake values in patients with stage I pulmonary adenocarcinoma. Eur J Cardiothorac Surg. 2009;35:712–6. https://doi.org/10.1016/j.ejcts.2008.12.030.CrossRefPubMed

19.

Okada M, Nakayama H, Okumura S, Daisaki H, Adachi S, Yoshimura M, et al. Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma. J Thorac Cardiovasc Surg. 2011;141:1384–91. https://doi.org/10.1016/j.jtcvs.2011.02.007.CrossRefPubMed

20.

Lin Y, Lin WY, Kao CH, Yen KY, Chen SW, Yeh JJ. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer. Anticancer Res. 2012;32:5087–91.PubMed

21.

Lin JT, Yang XN, Zhong WZ, Liao RQ, Dong S, Nie Q, et al. Association of maximum standardized uptake value with occult mediastinal lymph node metastases in cN0 non-small cell lung cancer. Eur J Cardiothorac Surg. 2016;50:914–9. https://doi.org/10.1093/ejcts/ezw109.CrossRefPubMed

22.

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244.CrossRefPubMed

23.

Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: A meta-analysis. PLoS ONE. 2016;11: e0146195. https://doi.org/10.1371/journal.pone.0146195.CrossRefPubMedPubMedCentral

24.

Ito H, Suzuki K, Mizutani T, Aokage K, Wakabayashi M, Fukuda H, et al. Long-term survival outcome after lobectomy in patients with clinical T1 N0 lung cancer. J Thorac Cardiovasc Surg. 2020. https://doi.org/10.1016/j.jtcvs.2019.12.072.CrossRefPubMed

25.

Terada Y, Isaka M, Harada H, Konno H, Kojima H, Mizuno T, et al. Radiotherapy for local recurrence of non-small-cell lung cancer after lobectomy and lymph node dissection-can local recurrence be radically cured by radiation? Jpn J Clin Oncol. 2020;50:425–33. https://doi.org/10.1093/jjco/hyz188.CrossRefPubMed

26.

Haruki T, Aokage K, Miyoshi T, Hishida T, Ishii G, Yoshida J, et al. Mediastinal nodal involvement in patients with clinical stage I non-small-cell lung cancer: possibility of rational lymph node dissection. J Thorac Oncol. 2015;10:930–6. https://doi.org/10.1097/JTO.0000000000000546.CrossRefPubMed

27.

Khullar OV, Fernandez FG, Perez S, Knechtle W, Pickens A, Sancheti MS, et al. Time is money: hospital costs associated with video-assisted thoracoscopic surgery lobectomies. Ann Thorac Surg. 2016;102:940–7. https://doi.org/10.1016/j.athoracsur.2016.03.024.CrossRefPubMed

28.

Hishida T, Saji H, Watanabe SI, Asamura H, Aokage K, Mizutani T, et al. A randomized Phase III trial of lobe-specific vs systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413). Jpn J Clin Oncol. 2018;48:190–4. https://doi.org/10.1093/jjco/hyx170.CrossRefPubMed

29.

Abughararah TZ, Jeong YH, Alabbood F, Chong Y, Yun JK, Lee GD, et al. Lobe-specific lymph node dissection in stage IA non-small-cell lung cancer: a retrospective cohort study. Eur J Cardiothorac Surg. 2021;59:783–90. https://doi.org/10.1093/ejcts/ezaa369.CrossRefPubMed

Title: Lobe-specific nodal dissection with intraoperative frozen section analysis for clinical stage-I non-small cell lung cancer: a validation study by propensity score matching
Authors: Mitsuhiro Isaka
Hideaki Kojima
Toru Imai
Hayato Konno
Tetsuya Mizuno
Toshiyuki Nagata
Shinya Katsumata
Takuya Kawata
Takashi Nakajima
Yasuhisa Ohde
Publication date: 11-05-2022
Publisher: Springer Nature Singapore
Keywords: NSCLC
Metastasis
NSCLC
Published in: General Thoracic and Cardiovascular Surgery / Issue 11/2022
Print ISSN: 1863-6705
Electronic ISSN: 1863-6713
DOI: https://doi.org/10.1007/s11748-022-01827-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Lobe-specific nodal dissection with intraoperative frozen section analysis for clinical stage-I non-small cell lung cancer: a validation study by propensity score matching

Abstract

Objective

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2022

Transcatheter tricuspid valve-in-valve implantation with bioprosthetic balloon expandable valve

Novel technique in frozen elephant trunk positioning method using the ostium of the coronary artery on transesophageal echocardiography as an index

Single direct right axillary artery cannulation using a modified Seldinger technique in minimally invasive cardiac surgery

Postoperative outcomes of valve reoperation are associated with the number of previous cardiac operations

Complex vs. simple segmentectomy: comparing surgical outcomes in the left upper division

VATS-assisted surgical stabilization of rib fractures in flail chest: 1-year follow-up of 105 cases